Achyut Healthcare Ltd vs Astrazeneca Pharma India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Achyut Healthcare Ltd is ₹ 5.02 as of 18 May 15:30 . The P/E Ratio of Achyut Healthcare Ltd changed from 342.5 on March 2022 to 163 on March 2025 . This represents a CAGR of -16.94% over 4 yearsThe P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 185.9 on March 2025 . This represents a CAGR of 18.16% over 5 years The Market Cap of Achyut Healthcare Ltd changed from ₹ 13.85 crore on March 2022 to ₹ 76.79 crore on March 2025 . This represents a CAGR of 53.45% over 4 yearsThe Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 21515 crore on March 2025 . This represents a CAGR of 23.38% over 5 years The revenue of Achyut Healthcare Ltd for the Dec '25 is ₹ 1.61 crore as compare to the Sep '25 revenue of ₹ 2.66 crore. This represent the decline of -39.47% The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 618.18 crore as compare to the Sep '25 revenue of ₹ 565.26 crore. This represent the growth of 9.36% The ebitda of Achyut Healthcare Ltd for the Dec '25 is ₹ 0.04 crore as compare to the Sep '25 ebitda of ₹ 0.19 crore. This represent the decline of -78.95% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 51.44 crore as compare to the Sep '25 ebitda of ₹ 76.06 crore. This represent the decline of -32.37% The net profit of Achyut Healthcare Ltd changed from ₹ 0.03 crore to ₹ 0 crore over 5 quarters. This represents a CAGR of -100.00% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 32.59 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Achyut Healthcare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 years .

About Achyut Healthcare Ltd

Achyut Healthcare Limited was incorporated as Achyut Securities Private Limited' on January 11, 1996 as a Private Limited Company under the Companies Act, 1956 with the Registrar of Companies, Gujarat, Dadra and Nagar Haveli.
The Company name was changed to Achyut Healthcare Private Limited', and a fresh Certificate of Incorporation dated November 26, 2002.
Subsequently, the Company got converted from a Private Limited to Public Limited and the name of the Company changed to Achyut Healthcare Limited', and a fresh Certificate of Incorporation dated November 30, 2021 was issued to the Company by Registrar of Companies, Gujarat at Ahmedabad. The Company is engaged in trading of Cenzure, Arpimune, Azathioprine IP, Everolimus, Mycophenolate Mofetil USP, Mycophenolate Sodium USP, Sirolimus, Tacrolimus USP, Infrared thermometer, Ascorbic Acid Coated Vitamin C, Calcium carbonate oyster, Cellulose acetate Phthalate, Chlorthalidone IP, Croscarmellose Sodium IP/USP, DIBasic Calcium Phosphate IP, DIEthyl Phthalate, Diltiazem Hydrochloride IP, Easy Coat Fc Titanium Dioxide, Escitalopram IP, Escitalopram Oxalate, Favipiravir among many other products.

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

FAQs for the comparison of Achyut Healthcare Ltd and Astrazeneca Pharma India Ltd

Which company has a larger market capitalization, Achyut Healthcare Ltd or Astrazeneca Pharma India Ltd?

Market cap of Achyut Healthcare Ltd is 118 Cr while Market cap of Astrazeneca Pharma India Ltd is 21,254 Cr

What are the key factors driving the stock performance of Achyut Healthcare Ltd and Astrazeneca Pharma India Ltd?

The stock performance of Achyut Healthcare Ltd and Astrazeneca Pharma India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Achyut Healthcare Ltd and Astrazeneca Pharma India Ltd?

As of May 18, 2026, the Achyut Healthcare Ltd stock price is INR ₹5.02. On the other hand, Astrazeneca Pharma India Ltd stock price is INR ₹8501.8.

How do dividend payouts of Achyut Healthcare Ltd and Astrazeneca Pharma India Ltd compare?

To compare the dividend payouts of Achyut Healthcare Ltd and Astrazeneca Pharma India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.